Investing.com -- Sanofi (EURONEXT:SAN) said Wednesday that its investigational therapy efdoralprin alfa has received orphan ...

December 17, 2025. Sanofi announced today that its Q4 2025 Aide memoire is available on the "Investors" page of the company's website: Fourth quarter & full year 2025 results (sanofi.com) As for each ...

Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema Additional orphan designation reinforces Sanofi’s commitment to developing treatments ...

Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments December 16, 2025 11:15 AM ...

Fintel reports that on December 15, 2025, ODDO BHF maintained coverage of Sanofi (OTCPK:SNYNF) with a Buy recommendation. Analyst Price Forecast Suggests 29.28% Upside As of November 17, 2025, the ...

Fintel reports that on December 15, 2025, BANCO SANTANDER maintained coverage of Sanofi (OTCPK:SNYNF) with a Outperform recommendation. Analyst Price Forecast Suggests 29.28% Upside As of November 17, ...

ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a U.S. phase I study.

Sanofi will not be pursuing approval of tolebrutinib for PPMS, and an FDA decision on the therapy in nonrelapsing SPMS will ...

Tolebrutinib failed to meet the primary endpoint in the phase 3 PERSEUS study involving patients with primary progressive multiple sclerosis.

The FDA contacted J&J right after ASH to discuss using a special fast pass on a multiple myeloma regimen. Elsewhere, a new ...

ADEL Inc., a biopharma company, has entered into an exclusive worldwide license agreement with Sanofi for the development and ...

South Korea-based ADEL said late on Monday that it has entered a $1.04 billion partnership with French drugmaker Sanofi to ...